UC San Diego

UC San Diego Previously Published Works

Title

Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV.

Permalink

<https://escholarship.org/uc/item/2wp7971q>

Journal

Journal of neurovirology, 27(1)

ISSN

1355-0284

Authors

Saloner, Rowan
Paolillo, Emily W
Heaton, Robert K
et al.

Publication Date

2021-02-01

DOI

10.1007/s13365-020-00925-1

Peer reviewed

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/348284014>

Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV

Article in *Journal of NeuroVirology* · January 2021

DOI: 10.1007/s13365-020-00925-1

CITATIONS

0

READS

19

12 authors, including:

Rowan Saloner

University of California, San Diego

30 PUBLICATIONS 168 CITATIONS

[SEE PROFILE](#)

Emily W. Paolillo

University of California, San Diego

35 PUBLICATIONS 293 CITATIONS

[SEE PROFILE](#)

Robert K. Heaton

University of California, San Diego

73 PUBLICATIONS 219 CITATIONS

[SEE PROFILE](#)

David J. Grelotti

Harvard University

18 PUBLICATIONS 112 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:

Kynurenine metabolites and chronic Inflammation: An in vitro and ex vivo study [View project](#)

clinical cases [View project](#)

Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV

Rowan Saloner^{1,2} · Emily W. Paolillo^{1,2} · Robert K. Heaton² · David J. Grelotti² · Murray B. Stein² · Andrew H. Miller³ · J. Hampton Atkinson² · Scott L. Letendre^{2,4} · Ronald J. Ellis^{2,5} · Igor Grant² · Jennifer E. Iudicello² · David J. Moore²

Received: 27 August 2020 / Revised: 8 October 2020 / Accepted: 27 October 2020
© Journal of NeuroVirology, Inc. 2021

Abstract

We examined the joint effects of depressive symptoms (Beck Depression Inventory-II (BDI-II)) and systemic inflammation (plasma C-reactive protein (CRP)) on longitudinal profiles of neurocognition in a cohort of 143 people with HIV (PWH) on antiretroviral therapy. Global neurocognition, processing speed, motor skills, and attention/working memory all worsened as CRP increased but only among PWH who, on average, exhibited moderate to severe depressive symptoms (BDI-II > 22). Findings suggest that some PWH with chronically elevated depressive symptoms may have an inflammatory subtype of depression and a particular vulnerability to neurocognitive changes that may respond to drugs targeting inflammation or its neural sequelae.

Keywords Depression · Inflammation · Cognition · HIV-associated neurocognitive disorder · C-reactive protein · Processing speed

Introduction

HIV disease can be effectively managed with antiretroviral therapy (ART), yet people with HIV (PWH) are disproportionately impacted by neuropsychiatric comorbidities that compromise HIV care (Bing et al. 2001; Gaynes et al. 2008; Pence et al. 2018). Among these comorbidities, depressed mood and depressive disorders are highly prevalent and predictive of adverse medical outcomes, including

functional disability, poorer ART adherence, accelerated HIV disease progression, and mortality (Leserman 2008; Pence et al. 2018; Rabkin 2008; Rubin and Maki 2019). The debilitating effects of depression may be partly related to its influence on neurocognitive functioning. Neurocognitive deficits of psychomotor slowing and poor attention are included in the DSM-5 criteria for major depressive disorder (MDD). Other diagnostic criteria such as sleep disturbance and fatigue are established risk factors for neurocognitive dysfunction (American Psychiatric Association 2013; Perini et al. 2019).

Consistent with the link between depression and functional decline in PWH, a recent longitudinal investigation from our group identified both acute and chronic effects of depressive symptoms on neurocognitive function among PWH (Paolillo et al. 2020a). Specifically, PWH who experienced greater chronicity of depressive symptoms exhibited steeper declines in neurocognition than those with a less severe burden of depressive symptoms over time. In addition to cumulative effects of depressive symptoms, within-person analyses demonstrated that neurocognition also varied concurrently with depressive symptoms, such that speed of information processing and motor skills were slower on visits when participants were experiencing more

✉ David J. Moore
djmoore@ucsd.edu

¹ San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, CA, USA

² Department of Psychiatry, University of California, La Jolla, San Diego, CA, USA

³ Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

⁴ Department of Medicine, University of California, La Jolla, San Diego, CA, USA

⁵ Department of Neurosciences, University of California, La Jolla, San Diego, CA, USA

severe depressive symptoms. The deleterious effects of high cumulative burden of depressive symptoms and transient depressive symptoms on neurocognition among PWH underscore the need to identify potential mechanism(s) that bridge these facets of neurobehavior.

One potential link between depression and neurocognition in PWH is inflammation (Ellis et al. 2020), a cardinal feature of HIV disease (Bandera et al. 2019; Beurel et al. 2020; Deeks et al. 2013). Similar to the chronicity of depressive symptoms, PWH often exhibit chronically elevated levels of systemic inflammation. In persons without HIV, strong evidence is emerging for a subgroup of depressed patients who present with high levels of generalized peripheral inflammation, commonly indexed by blood levels of c-reactive protein (CRP; Haroon et al. 2018; Miller et al. 2017). In these depressed patients elevated CRP is associated with aberrant functional connectivity in corticostriatal pathways, which is in turn linked to core depressive phenotypes characterized by anhedonia, apathy, and psychomotor slowing (Felger 2017; Felger et al. 2016). These corticostriatal structures, including the striatum and prefrontal cortex, are also prominent neuroanatomical substrates for HIV-associated neurocognitive disorders (HAND). Furthermore, patients with HAND consistently exhibit elevated levels of inflammation compared with those without HAND (Bandera et al. 2019; Iper et al. 2015; Woods et al. 2009). Given that systemic inflammation may act as a fulcrum upon which depression exerts both acute and chronic effects on neurocognition, the present communication expands on our prior longitudinal analysis by examining the joint influence of chronic systemic inflammation and depressive symptoms on neurocognition in a cohort of PWH on ART. Our primary aim was to examine the influence of generalized peripheral inflammation (i.e., plasma CRP) on neurocognition within individuals, and whether the strength of this relationship depended on the person's average intensity of depressive symptoms on the Beck Depression Inventory-II (BDI-II). We hypothesized that within individuals, neurocognition would be worse on visits with high CRP levels and that this relationship would be strongest among those with higher average BDI-II scores across the study period.

Methods

Participants

Participants were 143 PWH who underwent 3–6 study visits (12–59 months of follow-up; mean, 33 months) in NIH-funded longitudinal studies at the UCSD HIV Neurobehavioral Research Program. Participants provided written, informed consent to undergo study procedures, which were approved by the UCSD Institutional Review

Board. Participants were included in the present analysis if they completed at least three study visits (at least 6 months apart) with neuromedical, neurobehavioral, and CRP data, all collected on the same day. Consistent with Frascati research criteria for HAND (Antinori et al. 2007), participants were excluded if they had a baseline diagnosis of a psychotic or mood disorder with psychotic features, neurological or medical condition that may confound the interpretation of neuropsychological test results. Participants not taking ART at baseline also were excluded from analysis as this could confound interpretations of inflammation.

Procedures

HIV disease and treatment characteristics (i.e., nadir and current CD4 count, plasma HIV RNA, AIDS status, estimated duration of HIV disease, and ART use) and medical comorbidities (i.e., hypertension, hyperlipidemia, diabetes, and hepatitis C co-infection) were ascertained via comprehensive neuromedical evaluations consisting of a structured clinician-administered interview and standard laboratory assays. Levels of HIV RNA in plasma were measured via reverse transcriptase-polymerase chain reaction (Amplicor, Roche Diagnostics, Indianapolis, IN) and were considered undetectable below the lower limit of quantitation of 50 copies/ml. CRP was measured in blood plasma using a commercially available electrochemical luminescence immunoassay (MesoScale Discovery, USA) and run according to the manufacturers protocol. Biomarker precision was ensured by (a) assaying all specimens in duplicate, (b) repeating assays of specimens with coefficients of variation greater than 20%, (c) repeating 10% of all assays to assess operator and batch consistency, and (d) regularly assessing batch effects. CRP values were $\log_{10}$ -transformed to improve normality for use in statistical analyses.

Participants also underwent a comprehensive neurobehavioral evaluation including a standardized 7-domain battery of neuropsychological tests and self-report inventories of psychological functioning at each visit (Carey et al. 2004). Raw neuropsychological test scores were converted to practice-effect corrected scaled scores ($M = 10$; $SD = 3$) and averaged across the entire battery and within cognitive domains to generate global and domain-specific scaled scores, which were used as outcome variables (Cysique et al. 2011). The BDI-II was administered to assess depressive symptoms (Beck et al. 1996). Participants also were evaluated for DSM-IV lifetime and current (last 30 days) diagnoses of substance use disorders and Major Depressive Disorder (MDD) using the Composite International Diagnostic Interview (World Health Organization 1998).

Statistical analyses

Multilevel modeling was used to examine the within- and between-person effects of inflammation and depressive symptoms on global neurocognitive functioning over time. To determine the neurocognitive domains driving significant associations with global neurocognitive function, additional exploratory multilevel models for each domain-specific neurocognitive outcome were conducted. The within-person level of each multilevel model examined the acute effect of fluctuations in $\log_{10}$ plasma CRP (person-centered) and BDI-II score (person-centered) on neurocognition, covarying for time (i.e., years since baseline). CRP and BDI-II were both person-mean centered for use at the within-person level of this analysis, meaning that values of 0 represent the participant's own average, and negative and positive values represent measurements that are below and above their own average, respectively. Other potential time-varying covariates (i.e., plasma HIV RNA detectability, current CD4 count) were only included if they showed a significant ($p < 0.05$) within-person relationship with global scaled score, CRP, or BDI-II score. The between-person level of each multilevel model examined the chronic effect of participants' average levels of CRP and average BDI-II scores on their average levels of neurocognition across visits. Potential time-invariant covariates (i.e., all demographic and clinical factors except current and lifetime MDD) were only included if they showed a significant univariable relationship with global scaled score, CRP, or BDI-II score at baseline. To test the primary aim of this study, each multilevel model also included a cross-level interaction between person-centered CRP and average BDI-II score. Random intercepts and a random effect of person-centered CRP were specified. Unstandardized model estimates are reported. To follow-up on a significant cross-level interaction, the Johnson-Neyman method (Johnson and Neyman 1936; Preacher et al. 2006) was used to identify "regions of significance" (i.e., the levels of the moderator (average BDI-II score) at which the within-person relationship between CRP and neurocognition is significant). Finally, additional sensitivity analyses were conducted to examine whether results held among (1) a subset of participants who had undetectable plasma HIV RNA at all visits and (2) a subset of participants who did not meet criteria for a current substance use disorder at any visit. All analyses were conducted using R version 3.5.0. Multilevel models were examined with the "lme4" package (Bates et al. 2015).

Results

The study sample of 143 PWH was 80% male and 47% non-Hispanic White with a mean baseline age of 50.7 years (range 25–79) and mean baseline education of 13.4 years. Participants had an average of 33 months of follow-up (range

12–59 months). Participants' demographic, psychiatric, medical, and HIV disease characteristics from their baseline visit are displayed in Table 1. Neither plasma HIV RNA detectability nor current CD4 count were related to global neurocognition, CRP, or BDI-II score within persons, and thus, they were not included as covariates in the final multilevel models. Out of all remaining demographic and clinical characteristics that were considered for inclusion in the multilevel models as time-invariant covariates (i.e., all except current and lifetime MDD), seven were selected. Five were significantly related to lower global neurocognitive performance at baseline (i.e., older age, fewer years of education, non-White race/ethnicity (vs. White), hepatitis C, and hypertension), one was significantly related to higher plasma CRP (i.e., history of AIDS), and one was significantly related to higher BDI-II score (i.e., lifetime substance use disorder).

Table 1 Baseline demographic and clinical characteristics ($N = 143$)

	Mean (SD), Median (IQR), or n (%)
Demographics	
Age (years)	50.7 (9.6)
Sex (male)	115 (80%)
Years of education	13.4 (2.7)
Race/Ethnicity	
Non-Hispanic White	67 (47%)
Black	51 (36%)
Hispanic	18 (13%)
Other	7 (4%)
Employed	57 (40%)
Psychiatric and medical characteristics	
Beck Depression Inventory-II	9.9 (10.2)
Current major depressive disorder	18 (13%)
Lifetime major depressive disorder	81 (57%)
Current substance use disorder	10 (7%)
Lifetime substance use disorder	97 (68%)
Hepatitis C coinfection	34 (24%)
Hypertension	69 (48%)
Hyperlipidemia	51 (36%)
Diabetes	29 (20%)
$\log_{10}$ plasma C-reactive protein	6.3 (0.6)
HIV disease characteristics	
History of AIDS (yes)	105 (73%)
Estimated years living with HIV	16.1 (7.2)
Current CD4 count	569 (380–755)
Nadir CD4 count	120 (26–238)
Plasma HIV RNA detectability (undetectable)	110 (79%)
Antiretroviral therapy status (on)	143 (100%)

Substance use disorder includes meeting criteria for DSM-IV substance abuse or dependence for alcohol, cannabis, cocaine, methamphetamine, opioids, sedatives, hallucinogens, inhalants, or PCP

Current substance use disorder was also related to higher BDI-II score but was not included as a covariate due to multicollinearity with lifetime substance use disorder.

The cross-level interaction between person-centered CRP and average BDI-II score on global neurocognition was significant ($p = 0.012$; Table 2). The follow-up Johnson-Neyman analysis revealed that the within-person effect of CRP on global neurocognition is significantly negative only among participants whose average BDI-II scores are > 22.34 (Fig. 1a). Specifically, neurocognitive performance was worse on visits when CRP was higher (and vice versa), only among those with average BDI-II scores > 22.34 (Fig. 1b). Examination of other neurocognitive domain-specific outcomes (Table 2) showed that this was driven by significant effects in processing speed ($p = 0.047$), attention/working memory ($p = 0.040$), and fine motor skills ($p = 0.029$). Sensitivity analyses showed that results held among the subset of individuals who were virally suppressed at every visit ($n = 102$), and the subset of individuals who never met criteria for a current substance use disorder ($n = 124$).

Discussion

Within ART-treated PWH with moderate to severe depressive symptoms, we observed that global neurocognitive performance decreased as systemic inflammation increased relative to each person's average level of systemic inflammation. Conversely, among individuals who on average experienced none to mild levels of depressive symptoms across the study, neurocognition did not significantly vary as a function of average CRP or visit-specific CRP. These observations expand on our prior report (Paolillo et al. 2020a) by directly implicating inflammation as a moderator of the deleterious effects of cumulative burden of depressive symptoms on neurocognition among PWH. Moreover, these effects were robust to co-occurring medical conditions and remained significant in patients with fully-suppressed HIV across the entire study period, underscoring the relevance of inflammation and depressive symptoms for even successfully treated HIV.

Table 2 Multilevel model results for each neurocognitive outcome; values are unstandardized regression estimate (SE)

	Global	Verbal fluency	Executive functioning	Processing speed	Learning	Delayed recall	Attention/working memory	Motor skills
Within-person level								
CRP (person-centered) ^a	0.023 (0.094)	0.111 (0.145)	- 0.153 (0.185)	- 0.023 (0.136)	0.158 (0.187)	0.089 (0.204)	0.117 (0.176)	0.058 (0.171)
BDI-II (person-centered)	- 0.010 (0.007)	- 0.019 (0.011) ^b	- 0.010 (0.014)	- 0.015 (0.011)	- 0.013 (0.015)	0.002 (0.016)	- 0.003 (0.014)	0.002 (0.014)
Years since baseline	- 0.006 (0.027)	- 0.001 (0.004)	- 0.060 (0.050)	0.029 (0.039)	- 0.012 (0.054)	0.011 (0.058)	0.015 (0.049)	- 0.155 (0.049)**
Between-person level								
Average CRP	- 0.525 (0.294) ^b	- 0.375 (0.393)	- 0.238 (0.384)	- 0.607 (0.404)	- 0.546 (0.431)	- 0.438 (0.417)	- 0.584 (0.435)	- 0.609 (0.399)
Average BDI-II ^a	- 0.033 (0.016)*	- 0.035 (0.021)	- 0.022 (0.021)	- 0.022 (0.022)	- 0.027 (0.023)	- 0.021 (0.023)	- 0.032 (0.024)	- 0.074 (0.022)**
Cross-level interaction								
Person-centered CRP x Average BDI-II	- 0.025 (0.010)*	- 0.024 (0.015)	0.011 (0.019)	- 0.028 (0.014)*	- 0.022 (0.019)	-0.032 (0.021)	- 0.038 (0.018)*	- 0.039 (0.018)*

All multilevel models included the following time-invariant covariates at the between-person level: baseline age, sex (female vs. male), education, race/ethnicity (White vs. non-White), hepatitis C (yes vs. no), hypertension (yes vs. no), history of AIDS (yes vs. no), and past substance use disorder (yes vs. no)

* $p < 0.05$; ** $p < 0.01$

^aValues represent a conditional main effect

^b $p < 0.10$

Fig. 1 **a** Effect sizes (beta coefficients) of $\log_{10}$ plasma CRP (person-centered) on global neurocognitive scaled scores are plotted across average BDI-II scores. When the X-axis zero-line is included in the confidence band, the effect of $\log_{10}$ plasma CRP (person-centered) is not statistically significant at that average BDI-II value. The region of significance occurs to the right of the dashed line, showing that the within-person effect of $\log_{10}$ plasma CRP (person-centered) is significantly negative at average BDI-II levels greater than 22.34. This

indicates that among individuals whose average BDI-II levels are > 22.34 , their global neurocognition is lower (worse) on visits when their $\log_{10}$ CRP levels are higher than their own average and vice versa. **b** $\log_{10}$ plasma CRP (person-centered) by global scaled scores, stratified by average BDI-II scores using the empirically derived average BDI-II cut-point of 22.34. The within-person relationship between $\log_{10}$ plasma CRP (person-centered) and global neurocognition is negative in the high BDI-II group only

Using a multilevel model approach, we observed a significant cross-level interaction between average BDI-II scores and visit-specific CRP levels such that CRP exhibited a negative relationship with global neurocognition once average BDI-II scores reached 10 (based on visual inspection of Fig. 1a), and this effect reached formal statistical significance at an empirically-derived threshold of average BDI-II > 22.34 , indicating moderate to severe levels of depressive symptoms across the study period. This cross-level interaction between study-average depressive symptoms and visit-specific inflammation on global neurocognition was driven by statistically significant interactions in the domains of processing speed, fine motor skills, and attention/working memory. We previously detected acute deleterious effects of depressive symptoms on processing speed and motor skills in a separate sample of PWH (Paolillo et al. 2020a), and Montoya et al. (2019) found that higher peripheral inflammation mediated the adverse effect of HIV on motor skills (Montoya et al. 2019). In HIV-seronegative patients with MDD, higher plasma CRP has been related to elevated extra-synaptic glutamate in the basal ganglia as measured by magnetic resonance spectroscopy, which in turn related to anhedonia and slower performance on psychomotor tests (Haroon et al. 2016). A decline in speed of information processing may also contribute to our observations of poor attention/working memory among PWH with high depressive symptoms and CRP, as some attention components overlap with processing speed (e.g., focus/execute) and may be particularly compromised as working memory demands increase among PWH (Woods et al. 2009). Overall, our findings point toward a generalized pattern of cognitive and psychomotor

slowing coupled with poor attention/working memory, suggesting corticostriatal circuit involvement and consistent with the clinical phenotype of patients with depression and elevated CRP (Felger and Treadway 2017).

Our findings add to the growing body of longitudinal studies highlighting CRP as a salient predictor of adverse neurocognitive outcomes (Bettcher and Kramer 2014; Metti et al. 2014; Walker et al. 2019; Zheng and Xie 2018). In the general population, higher levels of CRP elevate risk for all-cause dementia by 45% and Alzheimer's disease by 21% (Koyama et al. 2013). In a recent analysis among women with HIV (Rubin et al. 2018), higher average intra-individual variability in CRP (average standard deviation of CRP levels) was the strongest predictor of neurocognitive impairment among a broader panel of peripheral immune biomarkers. As an acute phase reactant, blood concentrations of CRP rise during the inflammatory response to biological and psychological stress induced across multiple physiologic systems, including cardiometabolic, immune, and neurologic systems (Metti et al. 2014). Our current findings suggest that chronically depressed PWH, who already exhibit low levels of physiologic reserve due to HIV (Guaraldi et al. 2015; Oppenheim et al. 2018; Paolillo et al. 2020b), may exhibit an even lower capacity to withstand the neurocognitive stressors associated with an increase in systemic inflammation.

This study is among the first to employ robust statistical methods (i.e., multilevel models, Johnson-Neyman technique) to examine the combined effects of depressive symptoms and systemic inflammation on neurocognition in a well-characterized sample of PWH with at least three timepoints of longitudinal data. The study is not

without limitations. As a routinely assessed laboratory measure, CRP was the most widely available marker of inflammation in our research cohort dataset, which makes our findings clinically relevant. Nevertheless, although CRP has been associated with inflammatory markers in the blood and CSF in other studies (Felger et al. 2020), future studies may want to include additional peripheral and CNS markers of inflammation and immune activation to uncover granular mechanistic insights. Similarly, inclusion of monoamine neurotransmitters and their metabolites would help further disentangle the associations between depression, inflammation, and neurocognition among PWH (Saloner et al. 2020). The BDI-II importantly captures greater variation in global depressive symptomatology compared with a dichotomous disorder-based classification (e.g., MDD); however, future investigations should incorporate other instruments that comprehensively target dimensions of depression with putative relevance to inflammation, including anhedonia and apathy (Lee et al. 2018; Nakonezny et al. 2010; Yao et al. 2019). Our inclusion of inflammation, depression, and neurocognitive data importantly integrates physiological and behavioral units of analysis; yet, neuroimaging data would better allow for examining the underlying neurocircuitry, which would allow for examination of corticostriatal pathways in inflammation-related neurobehavioral disturbance among PWH. Last, given that non-Hispanic White men made up 42% of the overall study sample, these analyses should be replicated in larger samples with greater representation of women and racial/ethnic minorities.

Taken together, these findings demonstrate that among PWH with chronically elevated depressive symptoms, increases in systemic inflammation jointly track with neurocognitive impairments, particularly psychomotor slowing and diminished attention/working memory capacity. These novel observations among PWH are consistent with the growing body of literature among people without HIV pointing toward an inflammatory subtype of depressed individuals with neurobehavioral disturbances (e.g., altered motivation and motor activity) that may be non-responsive to standard antidepressants. Given that neurocognitive performance improved as CRP levels decreased among the subset of PWH with high cumulative depressive symptoms, reducing inflammation or its downstream impact on neurotransmitter systems such as dopamine and glutamate may confer greater neurocognitive benefits for these individuals than traditional antidepressants that preferentially target serotonergic and noradrenergic pathways (Miller and Raison 2016). Importantly, addressing these mood and neurocognitive symptoms in PWH may subsequently improve HIV-related medical outcomes and quality of life (Rooney et al. 2019; Rubin and Maki 2019).

Acknowledgements The San Diego HIV Neurobehavioral Research Center [HNRC] group is affiliated with the University of California, San Diego; the Naval Hospital, San Diego; and the Veterans Affairs San Diego Healthcare System, and includes Director: Robert K. Heaton, Ph.D., and Co-Director: Igor Grant, M.D.; Associate Directors: J. Hampton Atkinson, M.D.; Ronald J. Ellis, M.D., Ph.D.; and Scott Letendre, M.D.; Center Manager: Jennifer Iudicello, Ph.D.; Donald Franklin, Jr.; and Melanie Sherman; NeuroAssessment Core: Ronald J. Ellis, M.D., Ph.D. (P.I.); Scott Letendre, M.D.; Thomas D. Marcotte, Ph.D.; Christine Fennema-Notestine, Ph.D.; Debra Rosario, M.P.H.; and Matthew Dawson; NeuroBiology Core: Cristian Achim, M.D., Ph.D. (P.I.); Ana Sanchez, Ph.D.; and Adam Fields, Ph.D.; NeuroGerm Core: Sara Gianella Weibel, M.D. (P.I.); David M. Smith, M.D.; Rob Knight, Ph.D., and Scott Peterson, Ph.D.; Developmental Core: Scott Letendre, M.D. (P.I.) and J. Allen McCutchan; Participant Accrual and Retention Unit: J. Hampton Atkinson, M.D. (P.I.); Susan Little, M.D.; and Jennifer Marquie-Beck, M.P.H.; Data Management and Information Systems Unit: Lucila Ohno-Machado, Ph.D. (P.I.) and Clint Cushman; Statistics Unit: Ian Abramson, Ph.D. (P.I.); Florin Vaida, Ph.D. (Co-PI); and Anya Umlauf, M.S., Bin Tang, M.S.

Funding Data for this study were collected as part of two larger studies: (1) the HIV Neurobehavioral Research Center (HNRC; NIMH award P30MH062512) and (2) the CNS HIV Anti-Retroviral Therapy Effects Research program (CHARTER; NIH HHSN271201000036C and HHSN271201000030C). Additional funding was supported by NIA award F31AG064989 (stipend support to R.S.) and NIAAA award F31AA027198 (stipend support to E.W.P.).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Disclaimer The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the US Government.

References

- American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. *Neurology* 69:1789–1799
- Bandera A, Taramasso L, Bozzi G, Muscatello A, Robinson JA, Burdo TH, Gori A (2019) HIV-associated neurocognitive impairment in the modern ART era: are we close to discovering reliable biomarkers in the setting of virological suppression? *Frontiers in Aging Neuroscience* 11:187
- Bates D, Mächler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. *J Stat Softw* 1(1):2015
- Beck A, Steer R, Brown G (1996) Manual for Beck Depression Inventory II (BDI-II). TX, Psychology Corporation, San Antonio
- Bettcher BM, Kramer JH (2014) Longitudinal inflammation, cognitive decline, and Alzheimer's disease: a mini-review. *Clin Pharmacol Ther* 96:464–469
- Beurel E, Toups M, Nemeroff CB (2020) The bidirectional relationship of depression and inflammation: double trouble. *Neuron*.

- Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M (2001) Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. *Arch Gen Psychiatry* 58:721–728
- Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. *J Clin Exp Neuropsychol* 26:307–319
- Cysique LA, Franklin D Jr, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK, Group C, Group H (2011) Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. *J Clin Exp Neuropsychol* 33:505–522
- Deeks SG, Tracy R, Douek DC (2013) Systemic effects of inflammation on health during chronic HIV infection. *Immunity* 39:633–645
- Ellis RJ, Letendre SL, Atkinson JH, Clifford D, Collier AC, Gelman BB, Marra C, McCutchan JA, Morgello S, Sacktor N, Tang B, Heaton RK (2020) Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. *Brain, Behavior, & Immunity - Health*: 100121.
- Felger JC (2017) The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications. *Curr Top Behav Neurosci* 31:199–219
- Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, Le N-A, Feinberg R, Tansey MG, Miller AH (2020) What does plasma CRP tell us about peripheral and central inflammation in depression? *Molecular psychiatry* 25:1301–1311
- Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, Miller AH (2016) Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. *Molecular Psychiatry* 21:1358–1365
- Felger JC, Treadway MT (2017) Inflammation effects on motivation and motor activity: role of dopamine. *Neuropsychopharmacology* 42:216–241
- Gaynes BN, Pence BW, Eron JJ Jr, Miller WC (2008) Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosom Med* 70:505–511
- Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, Santoro A, Menozzi M, Mussi C, Mussini C, Kirkland S, Falutz J, Rockwood K (2015) A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. *Aids* 29:1633–1641
- Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, Felger JC, Miller AH (2018) Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. *Psychoneuroendocrinology* 95:43–49
- Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, Hu XP, Miller AH (2016) Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. *Mol Psychiatry* 21:1351–1357
- Iper JC, Brown GG, Bischoff-Grethe A, Connolly CG, Ellis RJ, Heaton RK, Grant I, Translational Methamphetamine ARCG (2015) HIV infection is associated with attenuated frontostriatal intrinsic connectivity: a preliminary study. *Journal of the International Neuropsychological Society : JINS* 21:203–213
- Johnson PO, Neyman J (1936) Tests of certain linear hypotheses and their application to some educational problems. *Statistical Research Memoirs* 1:57–93
- Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K (2013) The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. *The journals of gerontology Series A, Biological sciences and medical sciences* 68:433–440
- Lee Y, Subramaniapillai M, Brietzke E, Mansur RB, Ho RC, Yim SJ, McIntyre RS (2018) Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. *Therapeutic advances in psychopharmacology* 8:337–348
- Leserman J (2008) Role of depression, stress, and trauma in HIV disease progression. *Psychosom Med* 70:539–545
- Metti AL, Yaffe K, Boudreau RM, Simonsick EM, Carnahan RM, Satterfield S, Harris TB, Ayonayon HN, Rosano C, Cauley JA, Health ABCS (2014) Trajectories of inflammatory markers and cognitive decline over 10 years. *Neurobiol Aging* 35:2785–2790
- Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* 16:22–34
- Miller AH, Trivedi MH, Jha MK (2017) Is C-reactive protein ready for prime time in the selection of antidepressant medications? *Psychoneuroendocrinology* 84:206
- Montoya JL, Campbell LM, Paolillo EW, Ellis RJ, Letendre SL, Jeste DV, Moore DJ (2019) Inflammation relates to poorer complex motor performance among adults living with HIV on suppressive antiretroviral therapy. *J Acquir Immune Defic Syndr* 1999(80):15–23
- Nakonezny PA, Carmody TJ, Morris DW, Kurian BT, Trivedi MH (2010) Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. *Int Clin Psychopharmacol* 25:328–333
- Oppenheim H, Paolillo EW, Moore RC, Ellis RJ, Letendre SL, Jeste DV, Grant I, Moore DJ (2018) Neurocognitive functioning predicts frailty index in HIV. *Neurology* 91:e162–e170
- Paolillo EW, Pasipanodya EC, Moore RC, Pence BW, Atkinson JH, Grelotti DJ, Grant I, Heaton RK, Moore DJ (2020a) Cumulative burden of depression and neurocognitive decline among persons with HIV: a longitudinal study. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 84
- Paolillo EW, Sun-Suslow N, Pasipanodya EC, Morgan EE, Ellis RJ, Jeste DV, Moore DJ (2020) Pre-frailty predicts cognitive decline at 2-year follow-up in persons living with HIV. *Journal of NeuroVirology* 26:168–180
- Pence BW, Mills JC, Bengtson AM, Gaynes BN, Breger TL, Cook RL, Moore RD, Grelotti DJ, O'Cleirigh C, Mugavero MJ (2018) Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. *JAMA psychiatry* 75:379–385
- Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A (2019) Cognitive impairment in depression: recent advances and novel treatments. *Neuropsychiatric disease and treatment* 15:1249–1258
- Preacher KJ, Curran PJ, Bauer DJ (2006) Computational tools for probing interactions in multiple linear regression, multilevel modeling, and latent curve analysis. *Journal of educational and behavioral statistics* 31:437–448
- Rabkin JG (2008) HIV and depression: 2008 review and update. *Current HIV/AIDS Reports* 5:163–171
- Rooney AS, Moore RC, Paolillo EW, Gouaux B, Umlauf A, Letendre SL, Jeste DV, Moore DJ (2019) Depression and aging with HIV: associations with health-related quality of life and positive psychological factors. *J Affect Disord* 251:1–7
- Rubin LH, Benning L, Keating SM, Norris PJ, Burke-Miller J, Savarese A, Kumanan KN, Awadalla S, Springer G, Anastos K, Young M, Milam J, Valcour VG, Weber KM, Maki PM (2018) Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study. *Journal of neurovirology* 24:41–51

- Rubin LH, Maki PM (2019) HIV, depression, and cognitive impairment in the era of effective antiretroviral therapy. *Current HIV/AIDS Reports* 16:82–95
- Saloner R, Cherner M, Grelotti DJ, Paolillo EW, Moore DJ, Heaton RK, Letendre SL, Kumar A, Grant I, Ellis RJ (2020) Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. *Brain Behav Immun* 90:353–363
- Walker KA, Gottesman RF, Wu A, Knopman DS, Gross AL, Mosley TH Jr, Selvin E, Windham BG (2019) Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study. *Neurology* 92:e1256–e1267
- Woods SP, Moore DJ, Weber E, Grant I (2009) Cognitive neuropsychology of HIV-associated neurocognitive disorders. *Neuropsychol Rev* 19:152–168
- World Health Organization (1998) Composite Diagnostic International Interview (CIDI, version 2.1). World Health Organization: Geneva, Switzerland
- Yao H, Mizoguchi Y, Monji A, Yakushiji Y, Takashima Y, Uchino A, Yuzuriha T, Hashimoto M (2019) Low-grade inflammation is associated with apathy indirectly via deep white matter lesions in community-dwelling older adults: the sefuri study. *Int J Mol Sci* 20:1905
- Zheng F, Xie W (2018) High-sensitivity C-reactive protein and cognitive decline: the English Longitudinal Study of Ageing. *Psychol Med* 48:1381–1389
- Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.